PELTHOS THERAPEUTICS/$PTHS
1D1W1MYTD1Y5YMAX
Capital at risk
About PELTHOS THERAPEUTICS
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
- Ticker
- $PTHS
- Sector
- Health
- Primary listing
- AMEX
- Employees
- 92
- Headquarters
- Durham, United States
- Website
- pelthos.com
PTHS Metrics
BasicAdvanced
$84M
-
-$26.36
3.13
-
Price and volume
Market cap
$84M
Beta
3.13
52-week high
$37.50
52-week low
$18.19
Average daily volume
58K
Financial strength
Current ratio
1.982
Quick ratio
1.21
Long term debt to equity
-48.277
Total debt to equity
-48.707
Interest coverage (TTM)
-7.46%
Profitability
Gross margin (TTM)
75.58%
Net profit margin (TTM)
-199.50%
Operating margin (TTM)
-127.60%
Effective tax rate (TTM)
7.88%
Revenue per employee (TTM)
$470,000
Management effectiveness
Return on assets (TTM)
-49.98%
Return on equity (TTM)
2,161.07%
Valuation
Price to revenue (TTM)
1.66
Price to book
-54.35
Price to tangible book (TTM)
-1.28
Price to free cash flow (TTM)
-1.688
Free cash flow yield (TTM)
-59.24%
Free cash flow per share (TTM)
-12.997
Growth
Earnings per share change (TTM)
78.52%
3-year earnings per share growth (CAGR)
-11.47%
Upcoming events
No upcoming events
PTHS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.